Infigratinib
Sign in to save this workspacePrimary targets: FGFR2 · FDA status: FDA Approval Withdrawn
Selectivity scorecard
KISS
98.24
Gini
0.710
CATDS
0.025
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Infigratinib. Strongest target: FGFR1 at 99.2% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | FGFR1 | 99.2% | 0.8% |
| 2 | FGFR2 | 98.8% | 1.2% |
| 3 | FMS | 98.7% | 1.3% |
| 4 | FGFR3 | 98.6% | 1.4% |
| 5 | FGFR4 | 94.7% | 5.3% |
| 6 | TAOK2_TAO1 | 93.3% | 6.7% |
| 7 | DDR1 | 91.7% | 8.3% |
| 8 | LCK | 88.0% | 12.0% |
| 9 | LYN | 79.6% | 20.4% |
| 10 | C_KIT | 71.8% | 28.2% |
| 11 | FLT4_VEGFR3 | 69.4% | 30.6% |
| 12 | TIE2_TEK | 68.9% | 31.1% |
| 13 | FLT1_VEGFR1 | 67.5% | 32.5% |
| 14 | MEKK3 | 62.5% | 37.5% |
| 15 | EIF2AK2 | 61.7% | 38.3% |
| 16 | CDK4_CYCLIN_D3 | 59.4% | 40.6% |
| 17 | YES_YES1 | 56.7% | 43.3% |
| 18 | TAOK1 | 54.7% | 45.3% |
| 19 | EIF2AK4 | 52.6% | 47.4% |
| 20 | NEK2 | 51.0% | 49.0% |
Selectivity landscape
Where Infigratinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Infigratinib.
Atlas insights for Infigratinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target3%
Off-target97%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 1183.73 | |
| ALLOGRAFT_REJECTION | 4830.52 | |
| ANDROGEN_RESPONSE | 889.23 | |
| ANGIOGENESIS | 730.02 | |
| APICAL_JUNCTION | 5043.30 | |
| APICAL_SURFACE | 390.08 | |
| APOPTOSIS | 3142.33 | |
| BILE_ACID_METABOLISM | 379.65 | |
| CHOLESTEROL_HOMEOSTASIS | 516.35 | |
| COAGULATION | 532.18 | |
| COMPLEMENT | 2490.16 | |
| DNA_REPAIR | 915.50 | |
| E2F_TARGETS | 2255.98 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 916.44 | |
| ESTROGEN_RESPONSE_EARLY | 1418.83 | |
| ESTROGEN_RESPONSE_LATE | 1584.20 | |
| FATTY_ACID_METABOLISM | 496.70 | |
| G2M_CHECKPOINT | 2114.69 | |
| GLYCOLYSIS | 1650.67 | |
| HEDGEHOG_SIGNALING | 335.71 | |
| HEME_METABOLISM | 1194.31 | |
| HYPOXIA | 1766.91 | |
| IL2_STAT5_SIGNALING | 1435.12 | |
| IL6_JAK_STAT3_SIGNALING | 2865.72 | |
| INFLAMMATORY_RESPONSE | 2164.60 | |
| INTERFERON_ALPHA_RESPONSE | 383.44 | |
| INTERFERON_GAMMA_RESPONSE | 3200.03 | |
| KRAS_SIGNALING_DN | 426.98 | |
| KRAS_SIGNALING_UP | 1921.10 | |
| MITOTIC_SPINDLE | 3211.33 | |
| MTORC1_SIGNALING | 2161.67 | |
| MYC_TARGETS_V1 | 2035.49 | |
| MYC_TARGETS_V2 | 425.73 | |
| MYOGENESIS | 1299.70 | |
| NOTCH_SIGNALING | 63.95 | |
| OXIDATIVE_PHOSPHORYLATION | 1032.81 | |
| P53_PATHWAY | 1691.73 | |
| PANCREAS_BETA_CELLS | 167.32 | |
| PEROXISOME | 555.57 | |
| PI3K_AKT_MTOR_SIGNALING | 5151.20 | |
| PROTEIN_SECRETION | 1034.07 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 248.04 | |
| SPERMATOGENESIS | 754.67 | |
| TGF_BETA_SIGNALING | 791.44 | |
| TNFA_SIGNALING_VIA_NFKB | 1782.63 | |
| UNFOLDED_PROTEIN_RESPONSE | 790.02 | |
| UV_RESPONSE_DN | 2383.93 | |
| UV_RESPONSE_UP | 1798.14 | |
| WNT_BETA_CATENIN_SIGNALING | 922.68 | |
| XENOBIOTIC_METABOLISM | 1086.03 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.822 |
| SRR23303752 | — | 0.820 |
| aMVAC.P_005_TURBT_S223 | — | 0.804 |
| C3N-03420 | — | 0.803 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.803 |
Annotations
Sign in to read and post annotations.
Loading…